ReviewCureus2025
High-Sensitivity Cardiac Troponin as a Predictor of Adverse Events in Cardiac Sarcoidosis: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is a multisystem granulomatous disease with a higher incidence in African Americans and Scandinavians. Cardiac sarcoidosis causes arrhythmias, atrioventricular block, heart failure, and sudden death. Elevated high-sensitivity cardiac troponin T (hs-cTnT) and B-type natriuretic peptide (BNP) predict adverse outcomes despite left ventricular ejection fraction (LVEF) normalization. Corticosteroids, implantable cardioverter-defibrillators (ICDs), and angiotensin-converting enzyme (ACE) inhibitors remain key therapies, but evidence is limited, warranting a systematic review. This review searched five databases for English studies on cardiac sarcoidosis up to July 2025. Three observational studies met the patient-exposure-comparison-outcome (PECOS) criteria. Data extraction covered demographics, comorbidities, and hs-cTnT outcomes. Quality was assessed using the National Institutes of Health (NIH) tool, with narrative synthesis due to heterogeneity. This systematic review included three Japanese studies with 258 patients (142 low vs. 116 high hs-cTnT). High hs-cTnT was linked to older age, male predominance, higher BNP, lower LVEF, and worse renal function. Adverse outcomes were significantly more frequent, including cardiac death, ventricular tachycardia (VT)/ventricular fibrillation (VF), heart failure, and hospitalizations. Combined high hs-cTnT and BNP conferred the greatest risk. Imaging showed no major differences except for more right ventricular uptake in high hs-cTnT patients. This review shows that high hs-cTnT strongly predicts poor outcomes in cardiac sarcoidosis, independent of other factors. Combined with BNP, it refines risk stratification. Unlike imaging, hs-cTnT may uncover ongoing myocardial injury, supporting its role in guiding clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.